Evidence map›Paper›PMID 36224298›Full record

ArticleScientific reports2022

A comparative study of spike protein of SARS-CoV-2 and its variant Omicron (B.1.1.529) on some immune characteristics.

Ximeng Li, Wenjing Li, Zhuangzhuang Liu, Yuan Kang, Xiaoyu Zhang, Zhenlu Xu, Yuan Gao, Yun Qi

Open access · goldAbstract readComparative Study
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ximeng LiResearch Center for Pharmacology and Toxicology, Institute of Medicinal Plant Development, Chinese Academy of Medical Science and Peking Union Medical College, 151, North Ma Lian Wa Road, Haidian District, Beijing, 100193, People's Republic of China.
Wenjing LiResearch Center for Pharmacology and Toxicology, Institute of Medicinal Plant Development, Chinese Academy of Medical Science and Peking Union Medical College, 151, North Ma Lian Wa Road, Haidian District, Beijing, 100193, People's Republic of China.
Zhuangzhuang LiuResearch Center for Pharmacology and Toxicology, Institute of Medicinal Plant Development, Chinese Academy of Medical Science and Peking Union Medical College, 151, North Ma Lian Wa Road, Haidian District, Beijing, 100193, People's Republic of China.
Yuan KangResearch Center for Pharmacology and Toxicology, Institute of Medicinal Plant Development, Chinese Academy of Medical Science and Peking Union Medical College, 151, North Ma Lian Wa Road, Haidian District, Beijing, 100193, People's Republic of China.
Xiaoyu ZhangResearch Center for Pharmacology and Toxicology, Institute of Medicinal Plant Development, Chinese Academy of Medical Science and Peking Union Medical College, 151, North Ma Lian Wa Road, Haidian District, Beijing, 100193, People's Republic of China.
Zhenlu XuResearch Center for Pharmacology and Toxicology, Institute of Medicinal Plant Development, Chinese Academy of Medical Science and Peking Union Medical College, 151, North Ma Lian Wa Road, Haidian District, Beijing, 100193, People's Republic of China.
Yuan GaoResearch Center for Pharmacology and Toxicology, Institute of Medicinal Plant Development, Chinese Academy of Medical Science and Peking Union Medical College, 151, North Ma Lian Wa Road, Haidian District, Beijing, 100193, People's Republic of China. ygao@implad.ac.cn.
Yun QiResearch Center for Pharmacology and Toxicology, Institute of Medicinal Plant Development, Chinese Academy of Medical Science and Peking Union Medical College, 151, North Ma Lian Wa Road, Haidian District, Beijing, 100193, People's Republic of China. yqi@implad.ac.cn.
Chinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of Omicron variant raises great concerns because of its rapid transmissibility and its numerous mutations in spike protein (S-protein). S-protein can act as a pathogen-associated molecular pattern and complement activator as well as antigen. We compared some immune characteristics of trimer S-proteins for wild type (WT-S) and B.1.1.529 Omicron (Omicron-S) to investigate whether the mutations have affected its pathogenicity and antigenic shift. The results indicated that WT-S and Omicron-S directly activated nuclear factor-κB (NF-κB) and induced the release of pro-inflammatory cytokines in macrophages, but the actions of Omicron-S were weaker. These inflammatory reactions could be abrogated by a Toll-like receptor 4 antagonist TAK-242. Two S-proteins failed to induce the production of antiviral molecular interferon-β. In contrast to pro-inflammatory effects, the ability of two S-proteins to activate complement was comparable. We also compared the binding ability of two S-proteins to a high-titer anti-WT-receptor-binding domain antibody. The data showed that WT-S strongly bound to this antibody, while Omicron-S was completely off-target. Collectively, the mutations of Omicron have a great impact on the pro-inflammatory ability and epitopes of S-protein, but little effect on its ability to activate complement. Addressing these issues can be helpful for more adequate understanding of the pathogenicity of Omicron and the vaccine breakthrough infection.

Indexed as

COVID-19VaccinesAntiviral AgentsCytokinesEpitopesHumansInterferon-betaMembrane GlycoproteinsNF-kappa BPathogen-Associated Molecular Pattern MoleculesSARS-CoV-2Spike Glycoprotein, CoronavirusToll-Like Receptor 4Viral Envelope ProteinsAntiviral AgentsCytokinesEpitopesInterferon-betaMembrane GlycoproteinsNF-kappa BPathogen-Associated Molecular Pattern MoleculesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Toll-Like Receptor 4VaccinesViral Envelope Proteins

Identifiers

PMID36224298
PMCPMC9554390
OpenAlexW4304689892

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.